Review discusses innovations in surface-enhanced Raman spectroscopy assays for cardiac troponin detection, indicating potential for improving point-of-care testing.
Cardiac troponin (cTn) is widely recognized as the gold standard for the diagnosis of acute myocardial infarction (AMI), a leading cause of mortality worldwide. Point-of-care testing (POCT) for cTn necessitates rapid turnaround, cost-effectiveness, user-friendly operation, and portability, along with the highest level of accuracy to support timely and effective clinical decision-making. Surface-enhanced Raman spectroscopy (SERS) based assays possess several features suitable for POCT, including the flexibility to integrate with innovative platforms such as microfluidic systems and paper-based devices. In this review, we discuss the recent developments in SERS-based immuno (apta) assays for cTn detection, with a focus on detection strategies, employed platforms, and their feasibility for POCT. This review also outlines the improvements required in existing assays to meet POCT requirements, aiding in the design of future diagnostic assays.
No takes yet. Share an insight, caveat, or question.
Sreejith et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: